Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$389.27
neg -12.44
-3.10%
Today's Range: 388.08 - 403.45 | BIIB Avg Daily Volume: 1,830,400
Last Update: 04/27/15 - 4:14 PM EDT
Volume: 3,425,521
YTD Performance: 26.76%
Open: $401.75
Previous Close: $401.71
52 Week Range: $275.39 - $480.18
Oustanding Shares: 234,614,474
Market Cap: 100,949,915,873
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 9 12 12
Moderate Buy 1 1 1 1
Hold 3 5 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.47 1.73 1.53 1.53
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 34.78
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
34.78 34.80 28.22
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
20.35% 30.96% 241.90%
GROWTH 12 Mo 3 Yr CAGR
Revenue 46.50 0.92 0.24
Net Income 57.90 1.32 0.32
EPS 58.30 1.44 0.34
Earnings for BIIB:
EBITDA 3.41B
Revenue 8.51B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $4.12 $4.35 $16.96 $20.12
Number of Analysts 13 13 14 14
High Estimate $4.36 $4.52 $17.67 $21.83
Low Estimate $4.03 $4.22 $16.66 $19.25
Prior Year $3.49 $3.79 $13.79 $16.96
Growth Rate (Year over Year) 18.18% 14.82% 22.98% 18.64%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Apr 24, 2015 | 11:22 AM EDT

Biogen miss no reason to abandon big 4 of Big Pharma.

By

David Peltier

 | Apr 23, 2015 | 4:44 PM EDT

Telecom, utility and energy names led the way higher Thursday.

By

Robert Lang

 | Apr 22, 2015 | 10:52 AM EDT

Gilead's Relative Strength Index slope is very strong.

By

Robert Lang

 | Apr 22, 2015 | 10:00 AM EDT

Gilead's Relative Strength Index slope is very strong.

By

Jim Cramer

 | Apr 8, 2015 | 3:46 PM EDT

Even the second-tier biotechs are taking off.

By

James "Rev Shark" DePorre

 | Apr 7, 2015 | 4:37 PM EDT

The market is neither making progress nor shifting into a downtrend.

By

Gary Berman

 | Apr 6, 2015 | 1:20 PM EDT

After share price falls from March high, it may be ready to bounce.

By

Jim Cramer

 | Mar 30, 2015 | 5:39 AM EDT

An answer to those asking me what's worth buying.

By

Chris Laudani

 | Mar 26, 2015 | 8:00 AM EDT

But wait for a pullback before getting in.

By

Jim Cramer

 | Mar 24, 2015 | 6:29 PM EDT

Good buys kept getting overlooked.

Points well taken.

Hi Doug, your point is well taken - it's true that the relationship between the dollar and...
Hard to tell as Beats is lumped in with iPod and Apple TV -- but stripping away weak sales...

Okay, $140 billion? That's just sick lol.

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.